BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 24708472)

  • 1. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
    Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
    Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reparative therapy for acute ischemic stroke with allogeneic mesenchymal stem cells from adipose tissue: a safety assessment: a phase II randomized, double-blind, placebo-controlled, single-center, pilot clinical trial.
    Díez-Tejedor E; Gutiérrez-Fernández M; Martínez-Sánchez P; Rodríguez-Frutos B; Ruiz-Ares G; Lara ML; Gimeno BF
    J Stroke Cerebrovasc Dis; 2014; 23(10):2694-2700. PubMed ID: 25304723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
    Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
    Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
    Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
    Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Autologous Bone Marrow-derived Mesenchymal Stromal Cells Delay Acute Respiratory Distress Syndrome in Swine.
    Batchinsky AI; Roberts TR; Antebi B; Necsoiu C; Choi JH; Herzig M; Cap AP; McDaniel JS; Rathbone CR; Chung KK; Cancio LC
    Am J Respir Crit Care Med; 2023 Dec; 208(12):1283-1292. PubMed ID: 37797214
    [No Abstract]   [Full Text] [Related]  

  • 7. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
    Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
    Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
    Sadeghi B; Ringdén O; Gustafsson B; Castegren M
    Front Immunol; 2022; 13():963445. PubMed ID: 36426365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin α10β1-selected mesenchymal stem cells reduced hypercoagulopathy in a porcine model of acute respiratory distress syndrome.
    Edström D; Niroomand A; Stenlo M; Uvebrant K; Bölükbas DA; Hirdman G; Broberg E; Lim HC; Hyllén S; Lundgren-Åkerlund E; Pierre L; Olm F; Lindstedt S
    Respir Res; 2023 May; 24(1):145. PubMed ID: 37259141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
    Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
    Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
    Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
    CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
    Abraham E; Baughman R; Fletcher E; Heard S; Lamberti J; Levy H; Nelson L; Rumbak M; Steingrub J; Taylor J; Park YC; Hynds JM; Freitag J
    Crit Care Med; 1999 Aug; 27(8):1478-85. PubMed ID: 10470753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratracheal administration of umbilical cord blood-derived mesenchymal stem cells in a patient with acute respiratory distress syndrome.
    Chang Y; Park SH; Huh JW; Lim CM; Koh Y; Hong SB
    J Korean Med Sci; 2014 Mar; 29(3):438-40. PubMed ID: 24616596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
    Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
    Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.
    Zhu Y; Huang C; Zheng L; Li Q; Ge J; Geng S; Zhai M; Chen X; Yuan H; Li Y; Jia W; Sun K; Li Y; Ye T; Zhao Z; Liu H; Liu Z; Jiang H
    Stem Cell Res Ther; 2024 Apr; 15(1):122. PubMed ID: 38679727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Umbilical Cord-Derived Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome.
    Yip HK; Fang WF; Li YC; Lee FY; Lee CH; Pei SN; Ma MC; Chen KH; Sung PH; Lee MS
    Crit Care Med; 2020 May; 48(5):e391-e399. PubMed ID: 32187077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
    Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
    Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies.
    Quimby JM; Webb TL; Habenicht LM; Dow SW
    Stem Cell Res Ther; 2013 Apr; 4(2):48. PubMed ID: 23632128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Retention of Adipose Stromal Cells Following Intravenous Delivery Is Markedly Altered in the Presence of ARDS.
    Lu H; Cook T; Poirier C; Merfeld-Clauss S; Petrache I; March KL; Bogatcheva NV
    Cell Transplant; 2016; 25(9):1635-1643. PubMed ID: 26609693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.